1) Critics of inhaled insulin say, even with Afrezza, people with Diabetes still have to take injections. Is Mannkind planning to come up with basal inhaled insulin using the Technosphere particle in near future?
Mr. Mann: AFREZZATM addresses prandial (mealtime) glucose. But glucose is supplied by the liver between meals so in type 1 and late stage type 2 a person also needs a basal insulin. Basal insulin today requires one or two injections daily. However, for the 70% of type 2 diabetics who have not progressed to basal/bolus therapy. AFREZZA alone without basal injections has provided excellent control in a recent trial.
MannKind has been exploring various technologies to provide better basal insulins. We cannot yet speak about these.
